American Society of Cataract and Refractive Surgery

Investigational Optejet® Microdose Dispenser from Eyenovia Shows Promise in Improving Treatment for Myopia, Presbyopia and Patients Getting Eye Exams

Retrieved on: 
Monday, October 17, 2022
U.S. Securities and Exchange Commission, Time, Refractive surgery, Therapy, Water-dropper (calligraphy), Myopia, Regulation of tobacco by the U.S. Food and Drug Administration, Society, Patient, Naitō, Eye, Technology, Food, Marketing, Severe cognitive impairment, Cataract, CEO, American Society of Cataract and Refractive Surgery, Adult, GLOBE, Presbyopia, Forward-looking statement, Mydriasis, COVID-19, Compliance, Pharmaceutical industry, Dietary supplement, Matsui

The investigational Optejet dispenser administers ophthalmic solutions horizontally using the company's proprietary Microdose Array Print (MAP) technology.

Key Points: 
  • The investigational Optejet dispenser administers ophthalmic solutions horizontally using the company's proprietary Microdose Array Print (MAP) technology.
  • The Optejet dispenser is designed to administer 1/5 the volume of solution compared to a traditional eyedropper, making doses less likely to spill or run onto the patient's face.
  • "Traditional eye drops typically overdose a patient's eye with medication and preservatives, which can lead to significant dose-related side effects," said Michael Rowe, CEO of Eyenovia.
  • It found that nearly 90% of children using the Optejet once-daily treatment successfully complied with their treatment regimen.

Professional Basketball Player Max Strus Kicks Off New Season With Upgraded Vision From Life-Changing EVO ICL Lenses

Retrieved on: 
Wednesday, October 12, 2022
Sports, Medical Supplies, Licensing (Sports), Health, Marketing, Optical, Advertising, Communications, Medical Devices, Surgery, Basketball, Quality, NASDAQ, Cornea, CEO, Myopia, Athlete, ASCRS, Refractive surgery, Intraocular lens, Iris, ICL, Cataract, Inflammation, Eye, American Society of Cataract and Refractive Surgery, Nave, Ophthalmology, Literature, FDA, Astigmatism, Glaucoma, Prevalence, Lens, Review, Society, Dioptre, Lens (anatomy), Security (finance), Multimedia, Nursing, Intention, U.S. Securities and Exchange Commission, Night vision, STAAR, Allergen, Education, Retinal implant, Partnership, Glasses, Learning, Awareness, Social media, EVO, Medical device, Telescopic sight, Health insurance, Borosilicate glass, Strus, LASIK, Life, Patient

View the full release here: https://www.businesswire.com/news/home/20221012005068/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221012005068/en/
    Max Strus, American professional basketball player, practices his on-court skills with sharper vision from EVO ICL - a new FDA-approved vision correction lens designed for the correction/reduction of myopia (nearsightedness) and astigmatism.
  • Recently, Strus had EVO lenses implanted by his doctor to upgrade his vision and break free from the hassles of eyeglasses and contact lenses.
  • Following the EVO procedure, he went from struggling with the hassles of contact lenses, both on and off the court, to having clear vision better than 20/20.
  • Starting this month, Max Strus will share his journey in national and social media campaigns which will later be expanded globally.

Palatin Announces Presentation at the Eyecelerator@AAO 2022 Conference

Retrieved on: 
Thursday, September 29, 2022
Securities Exchange Act of 1934, American Academy, Inflammation, AAO, ASCRS, Academy, American Society of Cataract and Refractive Surgery, Twitter, NYSE, Retina, FDA, Refractive surgery, PTN, Drug Quality and Security Act, Duane syndrome, Association, Society, Private Securities Litigation Reform Act, Partnership, Securities Act of 1933, Calendar, DED, Metabolism, Biology, U.S. Securities and Exchange Commission, Patient, Melanocortin, Eye, Physician, Technology, Quality of life, Cataract, Tissue, Surgeon, Genomics, Biotechnology, Security (finance), Proteomics, Marketing, American Academy of Ophthalmology, Multimedia, 5-HT receptor, Kidney, Education, View, Video game, Pharmaceutical industry, Hospital, Palatine (disambiguation), Bremelanotide

CRANBURY, N.J., Sept. 29, 2022 /PRNewswire/ -- Palatin Technologies, Inc. ("Palatin") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced that Paul Kayne, Ph.D., Vice President of Biological Sciences at Palatin, presented today at the Eyecelerator@AAO in Chicago, IL. The presentation was one of several in the "Eyecelerator@ AAO 2022 - Therapeutics Showcase" general session.

Key Points: 
  • The presentation was one of several in the "Eyecelerator@ AAO 2022 - Therapeutics Showcase" general session.
  • For additional information regarding Palatin, please visit Palatin's website at www.Palatin.com and follow Palatin on Twitter at @PalatinTech.
  • Palatin is not responsible for updating for events that occur after the date of this press release.
  • Palatin Technologies and Vyleesi are registered trademarks of Palatin Technologies, Inc.
    View original content to download multimedia: https://www.prnewswire.com/news-releases/palatin-announces-presentation-...

Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia

Retrieved on: 
Wednesday, September 28, 2022
Institute, Safety, ASCRS, Efficiency, Risk, FDA, Food, Refractive surgery, American Society of Cataract and Refractive Surgery, Society, NDA, Intravitreal injection, PDUFA, Approximation error, Ophthalmology, Infection, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Orange Book, Cataract, Chloroprocaine, CA, Market, Research, Medicine, Optometry, Pharmaceutical industry, S.A

NASHVILLE, Tenn. and MENDRISIO, Switzerland, September 28, 2022 /PRNewswire/ -- Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, and Sintetica, S.A., a growing pharmaceutical company focused on analgesics, local anesthetics, and sterile injectable solutions, today jointly announced the U.S. Food and Drug Administration (FDA) approval of IHEEZO™ (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia. IHEEZO is a sterile, single-patient-use, physician-administered, ophthalmic gel preparation, containing no preservatives, that is safe and effective for ocular surface anesthesia. IHEEZO represents the first approved use in the U.S. ophthalmic market of chloroprocaine hydrochloride and the first branded ocular anesthetic approved for the U.S. ophthalmic market in nearly 14 years. IHEEZO is protected by an Orange Book-listed patent that is valid until 2038.

Key Points: 
  • IHEEZORepresentstheFirstApproved UseintheU.S.OphthalmicMarket of Chloroprocaine Hydrochloride and the First Branded Ocular Anesthetic Approved for the U.S. Ophthalmic Market in Nearly 14 Years
    IHEEZO was Licensed by Harrow for the U.S. and Canadian Markets From100-Year-OldInternationalPharmaceuticalCompanySintetica,S.A.
  • IHEEZO represents the first approved use in the U.S. ophthalmicmarketof chloroprocaine hydrochloride and the first branded ocular anesthetic approved for the U.S. ophthalmic market in nearly 14 years.
  • IHEEZO is protected by an Orange Book-listed patent that is valid until 2038.
  • Iwanttogivespecial thankstoourregulatorygroup, who while working with the Harrow team, performed extraordinarily well, resulting in this early U.S. market approval for this important new medicine."

Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia

Retrieved on: 
Wednesday, September 28, 2022
Institute, Safety, ASCRS, Efficiency, Risk, FDA, Food, Refractive surgery, American Society of Cataract and Refractive Surgery, Society, NDA, Intravitreal injection, PDUFA, Approximation error, Ophthalmology, Infection, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Optometry, Orange Book, Cataract, Chloroprocaine, CA, Market, Research, Medicine, Pharmaceutical industry, S.A

NASHVILLE, Tenn. and MENDRISIO, Switzerland, September 28, 2022 /PRNewswire/ -- Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, and Sintetica, S.A., a growing pharmaceutical company focused on analgesics, local anesthetics, and sterile injectable solutions, today jointly announced the U.S. Food and Drug Administration (FDA) approval of IHEEZO™ (chloroprocaine hydrochloride ophthalmic gel) 3% for ocular surface anesthesia. IHEEZO is a sterile, single-patient-use, physician-administered, ophthalmic gel preparation, containing no preservatives, that is safe and effective for ocular surface anesthesia. IHEEZO represents the first approved use in the U.S. ophthalmic market of chloroprocaine hydrochloride and the first branded ocular anesthetic approved for the U.S. ophthalmic market in nearly 14 years. IHEEZO is protected by an Orange Book-listed patent that is valid until 2038.

Key Points: 
  • NASHVILLE, Tenn. and MENDRISIO, Switzerland, September 28, 2022 /PRNewswire/ -- Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, and Sintetica, S.A., a growing pharmaceutical companyfocused onanalgesics,localanesthetics,andsterileinjectablesolutions,todayjointly announced the U.S. Food and Drug Administration (FDA) approval of IHEEZO (chloroprocaine hydrochloride ophthalmicgel)3%forocularsurface anesthesia.IHEEZOisasterile, single-patient-use, physician-administered,ophthalmicgelpreparation,containingnopreservatives,thatissafeandeffective for ocular surface anesthesia.
  • IHEEZO represents the first approved use in the U.S. ophthalmicmarketof chloroprocaine hydrochloride and the first branded ocular anesthetic approved for the U.S. ophthalmic market in nearly 14 years.
  • IHEEZO is protected by an Orange Book-listed patent that is valid until 2038.
  • Iwanttogivespecial thankstoourregulatorygroup, who while working with the Harrow team, performed extraordinarily well, resulting in this early U.S. market approval for this important new medicine."

Harrow Announces U.S. FDA Approval of IHEEZO™ (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia

Retrieved on: 
Tuesday, September 27, 2022
Research, Surgery, Medical Supplies, FDA, Clinical Trials, Biotechnology, Pharmaceutical, Health, Optical, Science, Institute, Safety, ASCRS, IV, Efficiency, COVID-19, Severe cognitive impairment, Risk, Refractive surgery, FDA, Food, Â, Anesthesia, American Society of Cataract and Refractive Surgery, Hypersensitivity, Society, Pharmacy, NDA, Intravitreal injection, PDUFA, Approximation error, Analgesic, Ophthalmology, Forward-looking statement, U.S. Securities and Exchange Commission, Infection, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, History, Eye, Physician, Orange Book, Full, Opacity (optics), Annual report, Cataract, Private Securities Litigation Reform Act, Patient safety, HCPS, Research, Security (finance), Marketing, SEC, Hospital, Optometry, Pharmaceutical industry, S.A

IHEEZO is a sterile, single-patientuse, physicianadministered, ophthalmic gel preparation, containing no preservatives, that is safe and effective for ocular surface anesthesia.

Key Points: 
  • IHEEZO is a sterile, single-patientuse, physicianadministered, ophthalmic gel preparation, containing no preservatives, that is safe and effective for ocular surface anesthesia.
  • IHEEZO represents the first approved use in the U.S. ophthalmic market of chloroprocaine hydrochloride and the first branded ocular anesthetic approved for the U.S. ophthalmic market in nearly 14 years.
  • Study 3 marks the first time a U.S. drug candidate was studied in a surgical model for FDA approval in the ocular surface anesthesia category.
  • Baum continued, Harrow currently provides perioperative medications for a significant number of the U.S. ophthalmic surgical procedures.

Xequel Bio To Present Corporate Overview and Clinical Trial Data at Eyecelerator® at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

Retrieved on: 
Tuesday, September 27, 2022
American Academy, Therapy, Inflammation, AAO, ASCRS, Acceleration, American Society of Cataract and Refractive Surgery, Fibrosis, DNA-binding protein, Refractive surgery, Association, Annual general meeting, Company, Society, Growth, Partnership, Granulation tissue, Patient, Eye, Physician, Technology, Solution, Cataract, Tissue, Science, Surgeon, Duane syndrome, GLOBE, American Academy of Ophthalmology, Pharmaceutical industry, Fine chemical, Dermatology, Ophthalmology

CHARLESTON, S.C. and FORT WORTH, Texas, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Xequel Bio, Inc., a clinical stage biopharmaceutical company developing ophthalmic and dermatologic therapeutics utilizing its patented new chemical entity aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide), announced today that Jerry St. Peter, Chief Executive Officer, will present a corporate overview and new iNexin™ (aCT1 ophthalmic solution) clinical data at the Eyecelerator conference on September 29, 2022, as part of the Annual Meeting of the American Academy of Ophthalmology (AAO) in Chicago, IL. AAO is the world's largest association of eye physicians and surgeons.

Key Points: 
  • In clinical and preclinical studies for the front of the eye, iNexin demonstrated acceleration of corneal healing and restoration of the ocular surface.
  • Xequel is well-positioned for future growth and value creation by leveraging our deep R&D expertise, proprietary platform and strong patent portfolio.
  • aCT1 is currently in clinical development for multiple indications across dermatology and ophthalmology, as well as in ongoing preclinical research in pulmonology.
  • The Companys lead clinical programs include Granexin gel in dermatology and iNexinTM ophthalmic solution in ophthalmology.

Opus Genetics Expands Board of Directors with Appointment of Global Ophthalmology Leader Dr. Adrienne Graves

Retrieved on: 
Tuesday, September 27, 2022
University, ASCRS, Alcon, LCA, Refractive surgery, AAV, Retinal degeneration, Â, Ophthalmology, Visual impairment, American Society of Cataract and Refractive Surgery, Gene, Retina, Industry, Patient, Himalayan Cataract Project, Genetics, CEO, Severe cognitive impairment, Cataract, Foundation, Science, RESEARCH, Leber congenital amaurosis, GLOBE, PARK, Triangle Park (Quezon City), Emeritus, Pharmaceutical industry, Opus

RESEARCH TRIANGLE PARK, N.C., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced the appointment of Adrienne Graves, Ph.D., to its board of directors.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Opus Genetics, a patient-first gene therapy company developing treatments for inherited retinal diseases, today announced the appointment of Adrienne Graves, Ph.D., to its board of directors.
  • Dr. Graves is the former CEO of Santen Inc., where she was responsible for growing the companys global presence and advancing multiple ophthalmic products through development to approval and commercialization.
  • Her nearly three decades of experience as a global executive and board member in the ophthalmology industry will be invaluable to Opus clinical and development efforts.
  • Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose.

Clearside Biomedical to Present Corporate Overview and Upcoming Catalysts at Eyecelerator at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

Retrieved on: 
Tuesday, September 27, 2022
American Academy, Retina, AAO, OASIS, ASCRS, COVID-19, CLS, American Society of Cataract and Refractive Surgery, Refractive surgery, Association, U.S. Securities and Exchange Commission, Annual general meeting, Choroid, Society, Private Securities Litigation Reform Act, Partnership, Concluding observations on the second periodic report of the Holy See, Patient, Clinical trial, Eye, Physician, MBA, Axitinib, Cataract, Annual report, Surgeon, NASDAQ, SCS, GLOBE, SEC, American Academy of Ophthalmology, Pharmaceutical industry, Clearside

There are multiple upcoming catalysts related to our internal CLS-AX program and from our development and commercialization partners.

Key Points: 
  • There are multiple upcoming catalysts related to our internal CLS-AX program and from our development and commercialization partners.
  • Eyecelerator is a partnership between the American Academy of Ophthalmology (AAO) and the American Society of Cataract and Refractive Surgery (ASCRS) to advance innovation in eye care by connecting mission-driven entrepreneurs, investors, physicians, and global strategic executives through next-generation business conferences.
  • Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS).
  • These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements.

Outlook Therapeutics® to Present at Eyecelerator @ AAO 2022

Retrieved on: 
Monday, September 26, 2022
American Academy, AAO, Bevacizumab, ASCRS, American Society of Cataract and Refractive Surgery, Biologics license application, FDA, Food, Refractive surgery, Society, Partnership, DME, Retina, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Physician, Benchmarking, Cataract, Nasdaq, BRVO, Government, AMD, GLOBE, BLA, American Academy of Ophthalmology, Pharmaceutical industry

ISELIN, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced it will present at Eyecelerator @ AAO 2022 taking place Thursday, September 29, 2022 in Chicago, Illinois.

Key Points: 
  • ISELIN, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced it will present at Eyecelerator @ AAO 2022 taking place Thursday, September 29, 2022 in Chicago, Illinois.
  • For more information, visit Eyecelerator @ AAO .
  • Outlook Therapeutics has submitted its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010 to treat wet AMD.
  • The submission is supported by Outlook Therapeutics wet AMD registration clinical program, which consists of three clinical trials: NORSE ONE, NORSE TWO, and NORSE THREE.